Ronda E. Stryker Sells 18,000 Shares of Stryker Corp. (SYK) Stock
Stryker Corp. (NYSE:SYK) Director Ronda E. Stryker sold 18,000 shares of Stryker Corp. stock in a transaction that occurred on Monday, September 26th. The shares were sold at an average price of $117.56, for a total transaction of $2,116,080.00. Following the sale, the director now directly owns 193,142 shares in the company, valued at approximately $22,705,773.52. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Stryker Corp. (NYSE:SYK) opened at 117.31 on Thursday. The firm has a 50-day moving average of $114.72 and a 200 day moving average of $113.32. Stryker Corp. has a 1-year low of $86.68 and a 1-year high of $123.55. The firm has a market cap of $43.91 billion, a P/E ratio of 27.65 and a beta of 0.71.
Stryker Corp. (NYSE:SYK) last released its quarterly earnings results on Thursday, July 21st. The medical technology company reported $1.39 EPS for the quarter, topping analysts’ consensus estimates of $1.37 by $0.02. Stryker Corp. had a net margin of 15.33% and a return on equity of 23.61%. The company had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.79 billion. On average, analysts predict that Stryker Corp. will post $5.76 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Monday, October 31st. Shareholders of record on Friday, September 30th will be given a dividend of $0.38 per share. The ex-dividend date is Wednesday, September 28th. This represents a $1.52 dividend on an annualized basis and a dividend yield of 1.30%. Stryker Corp.’s dividend payout ratio (DPR) is 35.85%.
Several hedge funds have recently added to or reduced their stakes in SYK. Lazard Asset Management LLC acquired a new stake in Stryker Corp. during the first quarter worth approximately $272,490,000. Winslow Capital Management LLC acquired a new stake in Stryker Corp. during the second quarter worth approximately $174,599,000. Capital Research Global Investors increased its stake in Stryker Corp. by 3.4% in the second quarter. Capital Research Global Investors now owns 32,980,782 shares of the medical technology company’s stock worth $3,952,087,000 after buying an additional 1,095,549 shares during the last quarter. BlackRock Fund Advisors increased its stake in Stryker Corp. by 20.1% in the second quarter. BlackRock Fund Advisors now owns 6,280,516 shares of the medical technology company’s stock worth $752,594,000 after buying an additional 1,051,648 shares during the last quarter. Finally, Emerald Acquisition Ltd. acquired a new stake in Stryker Corp. during the second quarter worth approximately $104,111,000. Institutional investors own 75.49% of the company’s stock.
Several analysts have recently commented on the stock. Zacks Investment Research lowered shares of Stryker Corp. from a “hold” rating to a “sell” rating in a research report on Tuesday. Brean Capital reaffirmed a “buy” rating and set a $125.00 price target (up previously from $121.00) on shares of Stryker Corp. in a research report on Monday, July 25th. Jefferies Group reaffirmed a “hold” rating and set a $120.00 price target (up previously from $113.00) on shares of Stryker Corp. in a research report on Monday, July 25th. Canaccord Genuity reaffirmed a “buy” rating and set a $130.00 price target on shares of Stryker Corp. in a research report on Sunday, July 24th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Stryker Corp. in a research report on Sunday, July 24th. Four research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the company’s stock. Stryker Corp. currently has a consensus rating of “Hold” and a consensus target price of $114.91.
Stryker Corp. Company Profile
Stryker Corporation (Stryker) is a medical technology company. The Company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Company’s Orthopaedics segment products consist of implants used in hip and knee joint replacements and trauma and surgeries. The Company’s MedSurg segment products consist of surgical equipment and surgical navigation systems (Instruments); endoscopic and communications systems (Endoscopy); patient handling and emergency medical equipment (Medical), and reprocessed and remanufactured medical devices (Sustainability), as well as other medical device products used in a range of medical specialties.
Receive News & Stock Ratings for Stryker Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corp. and related stocks with our FREE daily email newsletter.